Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...
Korea JoongAng Daily on MSN
Korean team develops AI model for customized cancer vaccine
A joint research team of the Korea Advanced Institute of Science and Technology (KAIST) and domestic biotechnology firm ...
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized Controlled ...
KAIST Professor Jung Kyoon Choi, Dr. Jeong Yeon Kim, and Dr. Jin Hyeon An >Neoantigens are unique markers that distinguish only cancer ...
Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's positive outcomes. The FELIX trial reported a 63% complete remission rate, with 42 ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback